Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XL888 With Vemurafenib Plus Cobimetinib in BRAF Mutated Melanoma
NCT02721459Phase 1Active, not recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Sep 2016
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of xl888 in melanoma, sponsored by Moffitt Cancer Center. Primary endpoint: Maximum Tolerated Dose at 12 months. Started Sep 2016; status: active, not recruiting.
02
Drugs
xl888
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02721459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02721459.